Abstract
Synergistic effects of immunotherapy with pembrolizumab or drugs targeting DNA damage, such as olaparib, might be used to overcome the limitations of radioligand therapy (RLT) with 177Lu-prostatespecificmembrane antigen (PSMA) inmetastasized castration-resistant prostate cancer. Here, we present 2 patients receiving such combination or sequential therapies. Methods: RLT was performed at 6- to 8-wk intervals after the patients either exhausted or were considered unfit for all approved conventional treatments. Patient 1 was on pembrolizumab for his squamous cell carcinoma of the skin, whereas patient 2 received RLT sequentially 4 wk after 3 mo of monotherapy with olaparib. Results: Both patients tolerated RLT without any significant hematotoxicity. Patient 2 showed a radiologic and biochemical response, whereas patient 1 achieved prostate-specific antigen stabilization after 3 therapy cycles. Conclusion: These cases indicate that RLT in combination with pembrolizumab or sequentially after olaparib might be well tolerated in single patients.
Original language | English |
---|---|
Pages (from-to) | 975-979 |
Number of pages | 5 |
Journal | Journal of Nuclear Medicine |
Volume | 62 |
Issue number | 7 |
DOIs | |
State | Published - 1 Jul 2021 |
Keywords
- 177Lu
- PSMA
- olaparib
- pembrolizumab